secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2025-04-10T23:59:59+00:00
Accession:  0001104659-25-033797
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Gain Therapeutics Announces Additional Preclinical Data and Phase 1b Study Design for GT-02287 in Parkinson's Disease
--------------------------------------------------------------------------------

- GT-02287 showed disease-modifying potential in GBA1 and idiopathic Parkinson's disease models, with biomarkers statistically reduced and lasting after drug washout.
- Phase 1b study ongoing; early biomarker analysis of enrolled participants expected mid-2025, including GBA1 mutation carriers and non-carriers.
- Complete Phase 1b endpoint analysis after 90 days of treatment anticipated in Q4 2025, guiding Phase 2 design in H2 2025.
- Oral presentation at AD/PD 2025 highlighted behavioral and biomarker data supporting GT-02287's disease-modifying capacity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925033797/0001104659-25-033797-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465925033797/tm2512000d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-033797

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer